EUVIMEDEUVIMED entdecken
Crossref

Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

Richard LeBlanc iD, Hira Mian iD, Donna Reece iD, Jiandong Su iD, Esther Masih-Khan iD, Michael Chu, Victor Jimenez-Zepeda iD, Michael Sebag, Kevin Song, Martha Louzada iD, Rami Kotb, Alissa Visram iD und 8 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Richard LeBlanc und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Janssen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although daratumumab‐containing regimens improve multiple myeloma (MM) outcomes, recurrence is inevitable. Methods and Objective We performed a retrospective study using the Canadian Myeloma Research Group Database to benchmark the efficacy of carfilzomib‐ or pomalidomide‐based therapies immediately following progression on daratumumab treatment.

Results

We identified 178 such patients; median number of prior lines of therapy was 3, 97% triple‐class exposed, and 60% triple‐class refractory. In our cohort, 75 received a subsequent carfilzomib‐based therapy, 79 received a pomalidomide‐based therapy, and 24 received a treatment with both immunomodulatory drug (IMiD) and proteasome inhibitor (PI) using carfilzomib and/or pomalidomide. The median progression‐free survival (PFS) and overall survival (OS) for the entire cohort were 4.5 and 14.2 months, respectively. Carfilzomib‐based therapy yielded a median PFS and OS of 4.5 and 10.2 months, respectively, compared to 5.2 and 21.7 months for pomalidomide‐based therapy. Patients who received both IMiD and PI with carfilzomib and/or pomalidomide had a median PFS and OS of 4.1 and 14.5 months, respectively.

Conclusion

Our observations demonstrate the poor outcome of MM patients when standard regimens based on carfilzomib and/or pomalidomide are utilized directly after daratumumab‐based therapy given in the relapsed setting. Novel therapies, including immune therapies, are urgently needed to improve the outcomes of these daratumumab‐exposed patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansOligopeptidesFemaleMaleAgedCanadaMiddle AgedAntibodies, MonoclonalTreatment OutcomeThalidomideRetrospective StudiesRecurrenceDatabases, FactualAdultAged, 80 and over

Stichwörter der Autor:innen

carfilzomibmultiple myelomapomalidomidepost-daratumumabreal-world data

Substanzen

daratumumabcarfilzomibOligopeptidespomalidomideAntibodies, MonoclonalThalidomide

Autor:innen und Institutionen

  • Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada.
  • Juravinski Cancer Centre (Hamilton-CCO), Hamilton, Ontario, Canada.
  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Canadian Myeloma Research Group, Toronto, Ontario, Canada.
  • Cross Cancer Institute, Edmonton, Alberta, Canada.
  • Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Richard LeBlanc, Hira Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Victor Jimenez-Zepeda, Martha Louzada, Alissa Visram, Darrell White, Julie Stakiw, Antony Reiman, Engin Gul, Christopher Venner

Förderung

  • Janssen Inc

Zitieren

APA

LeBlanc, R., Mian, H., Reece, D., Su, J., Masih-Khan, E., Chu, M., Jimenez-Zepeda, V., Sebag, M., Song, K., Louzada, M., Kotb, R., Visram, A., White, D., Stakiw, J., Reiman, A., Aslam, M., Bergstrom, D., Kaedbey, R., Gul, E., & Venner, C. (2023). Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal of Haematology. https://doi.org/10.1111/ejh.14082

Vancouver

LeBlanc R, Mian H, Reece D, Su J, Masih-Khan E, Chu M, et al. Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal of Haematology. 2023. doi:10.1111/ejh.14082

BibTeX
@article{LeBlanc2023,
  author = {LeBlanc, Richard and Mian, Hira and Reece, Donna and Su, Jiandong and Masih-Khan, Esther and Chu, Michael and Jimenez-Zepeda, Victor and Sebag, Michael and Song, Kevin and Louzada, Martha and Kotb, Rami and Visram, Alissa and White, Darrell and Stakiw, Julie and Reiman, Antony and Aslam, Muhammad and Bergstrom, Debra and Kaedbey, Rayan and Gul, Engin and Venner, Christopher},
  title = {Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14082}
}
Kostenlos starten →